Population Studies: Longitudinal immunological profiling (Milestone 1.G)
Achieved
Timeline Start - End
2018 - 2024Research Implementation Area
Population Studies and Precision MedicineAugment current and future human cohorts with more advanced, longitudinal immunological profiling (e.g. Cytof) to enable precision medicine research and to better understand the roles of the different arms of the central nervous system and peripheral immunity in brain aging and AD.
Success Criteria
- Provide supplemental funding to support longitudinal immunologic profiling to existing and newly launched mid-life and aging cohorts with rich-phenotypic data on brain health.
Summary of Key Accomplishments
The second phase of the Accelerating Medicines Partnership® for AD (AMP AD 2.0) will conduct longitudinal immune profiling in a well-phenotyped cohort of diverse participants to establish individual trajectories of immunological aging and their relationship to AD. It will develop a rich data/analytical resource that will capture a population-based sample of trajectories of immunological aging. These data will be made available to the research community via the NIA-supported AD Knowledge Portal.
The key accomplishments summary is current as of July 2022.
Accomplishments/Implementation Activities
Funding Initiatives
Research Programs and Resources
- AMP-AD 2.0 Precision Medicine Approach to Target and Biomarker Discovery
- Immune Cells in Alzheimer’s Disease and Related Dementias in the Jackson Heart Study
- Columbia ADRC Neuroimmunology Core